Delisting riskPopularity #4,541
Imunon (IMNN)
Developing localized DNA immunotherapy for advanced ovarian cancer.
$1.42
vs last close−0.09 (−5.96%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 7.58% | 318.7K shares | |
|---|---|---|---|
| 23 holders · as of Jun 30, 2026 | |||
| Insiders | 7.62% | 320.4K shares | |
| 10 holders · as of Sep 15, 2026 | |||
| Other | 84.80% | 3.56M shares | |
| remainder | |||
4.20M company shares as of Sep 5, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (5.61M in the company's Sep 23, 2026 report, 4.20M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
23 holders · 318.7K shares · 7 new positions · 9 increased · 4 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 144.8K | 3.45% | −203.6K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 47.0K | 1.12% | −1.1K | Aug 13, 2026 |
| Riverview Capital Advisers, LLC | 34.4K | 0.82% | 0 | Aug 13, 2026 |
| Geode Capital Management, LLC | 31.6K | 0.75% | −1.6K | Aug 12, 2026 |
| Virtu Financial LLC | 17.5K | 0.42% | +17.5Knew | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | 13.3K | 0.32% | 0 | Aug 13, 2026 |
| Northern Trust Corp | 10.3K | 0.25% | +10.3Knew | Aug 13, 2026 |
| UBS Group AG | 5.2K | 0.12% | +4.6K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 396.7K | 13G | May 15, 2026 |
| Opportunity Master Fund, SPC – Segregated Master Portfolio Bincl. Capital LLC, Khatri | 9.90% | 13G | Nov 14, 2024 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,525 | $1.56 | 2,896 |
| Aug 17, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,449 | $1.63 | 2,896 |
| Aug 3, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,541 | $1.57 | 2,896 |
| Jul 20, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 2,150 | $1.78 | 2,896 |
| Jul 6, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 920 | $1.88 | 2,896 |
| Jun 29, 2026 | Susan Eylwardofficer: General Counsel and Corp Sec | Sale | 11,800 | $1.75 | 2,896 |
House and Senate disclosures
Not reported.
